EMA Speeds Up Review of Metastatic Pancreatic Cancer Drug
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has initiated a phased review of data for daraxonrasib, a medicine...
South Korean Drug Exports Top $10 Billion for First Time
The South Korean pharmaceutical industry reached a significant commercial landmark in 2025, fueled by a sharp rise in international demand for drug exports and...
Top Picks: GMP Training Companies Elevating North American Pharma Standards
The pharmaceutical industry values providing safe and effective medication for its consumers. Good Manufacturing Practices (GMP) are critical in refining the drug manufacturing processes...
Z-Library and the Reduction of Uninformed Medical Decisions
Modern health choices often rest on fragile ground. Many people rely on quick advice or scattered notes. This habit can lead to gaps in...
How To Reduce Sample Interference in CLIA Assays Effectively
You run the assay. The values come back off. Not catastrophically wrong, just inconsistent enough to make you doubt everything. You've checked the protocol...
NLRC5 ELISA Kit Advances Quantification Of Immune Biomarkers
You run the assay, and at first, the numbers look acceptable. When working with an NLRC5 ELISA Kit, this kind of early confidence is...
Eli Lilly GLP-1 Diabetes and Obesity Drug Drive China Pledge
Eli Lilly and Company is indeed a giant in the pharmaceutical industry, and its GLP-1 diabetes and obesity drug franchise has made it even bigger....
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...